MLSS
Milestone Scientific Inc.
There isn't enough reported data to score MLSS yet.
MLSS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MLSS's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
MLSS PE Valuation
MLSS has no meaningful PE right now: it lost money over the past year.
MLSS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MLSS's losses to shrink, with revenue growing.
MLSS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.05 | +$0.04 |
| Q1 2026 | -$0.06 | +$0.01 |
| Q4 2025 | -$0.07 | $0.00 |
| Q3 2025 | -$0.08 | -$0.01 |
| Q2 2025 | -$0.09 | -$0.02 |
| Q1 2025 | -$0.07 | +$0.03 |
| Q4 2024 | -$0.07 | +$0.03 |
| Q3 2024 | -$0.07 | +$0.03 |
MLSS is still losing money, but far less than before: $0.05 per share over the past year, against $0.21 at its worst in mid-2020.
MLSS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.8M | +22% |
| Q1 2026 | $2.2M | -3.2% |
| Q4 2025 | $2.1M | +2.2% |
| Q3 2025 | $2.4M | -6.1% |
| Q2 2025 | $2.3M | +25% |
| Q1 2025 | $2.2M | -0.7% |
| Q4 2024 | $2M | -11% |
| Q3 2024 | $2.5M | +22% |
MLSS's revenue has held roughly level: $3M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -37% | +27 points |
| Q1 2026 | -38% | +51 points |
| Q4 2025 | -52% | +49 points |
| Q3 2025 | -48% | +10 points |
| Q2 2025 | -64% | +32 points |
| Q1 2025 | -89% | -24 points |
| Q4 2024 | -101% | -14 points |
| Q3 2024 | -58% | +15 points |
MLSS's operating margin was −37% last quarter, up 27 points from the same quarter a year ago, near the top of its range since 2019.
MLSS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$589.3K | +$1.2M |
| Q1 2026 | $85.2K | +$1.1M |
| Q4 2025 | -$229.2K | +$1.3M |
| Q2 2025 | -$1.8M | -325% |
| Q1 2025 | -$1M | +$210K |
| Q4 2024 | -$1.5M | -$265.7K |
| Q3 2024 | -$973.9K | +$79.3K |
| Q2 2024 | $783.7K | +$1.8M |
MLSS has burned cash in almost every quarter: −$2M over the past year, against −$3M the year before.
MLSS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.5% | +8.1M shares |
| 1 year | +13% | +11.1M shares |
| 3 years | +29% | +20.8M shares |
| 5 years | +35% | +23.9M shares |
| Available history | +95% | +45.4M shares |
MLSS has 93M diluted shares, up 13% from a year ago.
MLSS Net Leverage
MLSS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MLSS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 4.7 | Oversold |
MLSS's weekly RSI is 38 (neutral) and its Stochastic is 5 (oversold).
MLSS PE vs Healthcare Sector
MLSS has no meaningful PE right now: it lost money over the past year.
MLSS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.33 | 12% below |
| 20 week MA | $0.39 | 26% below |
| 50 week MA | $0.35 | 17% below |
| 100 week MA | $0.57 | 49% below |
| 200 week MA | $0.70 | 59% below |
MLSS is in a downtrend: it's below all five of its weekly moving averages, and 59% below its 200-week average.
MLSS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.38 | $2.02 | +46% |
| 2021 | $2.02 | $2.13 | +5.4% |
| 2022 | $2.13 | $0.45 | -79% |
| 2023 | $0.45 | $0.69 | +53% |
| 2024 | $0.69 | $0.88 | +28% |
| 2025 | $0.88 | $0.29 | -67% |
| 2026 YTD | $0.29 | $0.29 | 0% |
MLSS has finished higher in four of the last six years. It's roughly flat so far in 2026.